CTLA-4 blockade was associated with potent T cell proliferation in response to autologous and allogeneic CLL B cells, suggesting that this approach could represent a therapeutic opportunity to enhance an immune response against leukemia cells. The gene discussed is CTLA4; the disease is B-cell chronic lymphocytic leukemia.